SITC 2022 | Treating PD-L1-positive NSCLC with immunotherapy alone vs chemoimmunotherapy

Biagio Ricciuti, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the current role of PD-(L)1 inhibitors in treating non-small cell lung cancer (NSCLC). The Phase III KEYNOTE-042 trial (NCT02220894) of pembrolizumab alone versus chemotherapy demonstrated the superiority of immunotherapy over chemotherapy. However, patients with PD-L1 levels of less than 50% did not benefit from monotherapy, highlighting the need for personalized treatment. The INSIGNIA trial (NCT03793179) will assess immunotherapy alone versus chemoimmunotherapy. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.